-
International Journal of Molecular... Nov 2020is an opportunistic human pathogen causing devastating acute and chronic infections in individuals with compromised immune systems. Its highly notorious persistence in... (Review)
Review
is an opportunistic human pathogen causing devastating acute and chronic infections in individuals with compromised immune systems. Its highly notorious persistence in clinical settings is attributed to its ability to form antibiotic-resistant biofilms. Biofilm is an architecture built mostly by autogenic extracellular polymeric substances which function as a scaffold to encase the bacteria together on surfaces, and to protect them from environmental stresses, impedes phagocytosis and thereby conferring the capacity for colonization and long-term persistence. Here we review the current knowledge on biofilms, its development stages, and molecular mechanisms of invasion and persistence conferred by biofilms. Explosive cell lysis within bacterial biofilm to produce essential communal materials, and interspecies biofilms of and commensal which impedes virulence and possibly improves disease conditions will also be discussed. Recent research on diagnostics of infections will be investigated. Finally, therapeutic strategies for the treatment of biofilms along with their advantages and limitations will be compiled.
Topics: Animals; Biofilms; Humans; Pseudomonas Infections; Pseudomonas aeruginosa; Quorum Sensing
PubMed: 33212950
DOI: 10.3390/ijms21228671 -
World Journal of Microbiology &... Nov 2019Pseudomonas aeruginosa is a common, Gram-negative environmental organism. It can be a significant pathogenic factor of severe infections in humans, especially... (Review)
Review
Pseudomonas aeruginosa is a common, Gram-negative environmental organism. It can be a significant pathogenic factor of severe infections in humans, especially in cystic fibrosis patients. Due to its natural resistance to antibiotics and the ability to form biofilms, infection with this pathogen can cause severe therapeutic problems. In recent years, metabolomic studies of P. aeruginosa have been performed. Therefore, in this review, we discussed recent achievements in the use of metabolomics methods in bacterial identification, differentiation, the interconnection between genome and metabolome, the influence of external factors on the bacterial metabolome and identification of new metabolites produced by P. aeruginosa. All of these studies may provide valuable information about metabolic pathways leading to an understanding of the adaptations of bacterial strains to a host environment, which can lead to new drug development and/or elaboration of new treatment and diagnostics strategies for Pseudomonas.
Topics: Adaptation, Physiological; Genome, Bacterial; Host Microbial Interactions; Metabolic Networks and Pathways; Metabolome; Metabolomics; Pseudomonas aeruginosa
PubMed: 31701321
DOI: 10.1007/s11274-019-2739-1 -
International Journal of Molecular... Mar 2021is a dominant pathogen in people with cystic fibrosis (CF) contributing to morbidity and mortality. Its tremendous ability to adapt greatly facilitates its capacity to... (Review)
Review
is a dominant pathogen in people with cystic fibrosis (CF) contributing to morbidity and mortality. Its tremendous ability to adapt greatly facilitates its capacity to cause chronic infections. The adaptability and flexibility of the pathogen are afforded by the extensive number of virulence factors it has at its disposal, providing with the facility to tailor its response against the different stressors in the environment. A deep understanding of these virulence mechanisms is crucial for the design of therapeutic strategies and vaccines against this multi-resistant pathogen. Therefore, this review describes the main virulence factors of and the adaptations it undergoes to persist in hostile environments such as the CF respiratory tract. The very large genome (5 to 7 MB) contributes considerably to its adaptive capacity; consequently, genomic studies have provided significant insights into elucidating evolution and its interactions with the host throughout the course of infection.
Topics: Adaptation, Physiological; Animals; Biofilms; Humans; Lung; Pseudomonas aeruginosa; Quorum Sensing; Virulence Factors
PubMed: 33803907
DOI: 10.3390/ijms22063128 -
Annals of Clinical Microbiology and... Sep 2020Multi-Drug Resistant (MDR) Pseudomonas aeruginosa is one of the most important bacterial pathogens that causes infection with a high mortality rate due to resistance to... (Review)
Review
Multi-Drug Resistant (MDR) Pseudomonas aeruginosa is one of the most important bacterial pathogens that causes infection with a high mortality rate due to resistance to different antibiotics. This bacterium prompts extensive tissue damage with varying factors of virulence, and its biofilm production causes chronic and antibiotic-resistant infections. Therefore, due to the non-applicability of antibiotics for the destruction of P. aeruginosa biofilm, alternative approaches have been considered by researchers, and phage therapy is one of these new therapeutic solutions. Bacteriophages can be used to eradicate P. aeruginosa biofilm by destroying the extracellular matrix, increasing the permeability of antibiotics into the inner layer of biofilm, and inhibiting its formation by stopping the quorum-sensing activity. Furthermore, the combined use of bacteriophages and other compounds with anti-biofilm properties such as nanoparticles, enzymes, and natural products can be of more interest because they invade the biofilm by various mechanisms and can be more effective than the one used alone. On the other hand, the use of bacteriophages for biofilm destruction has some limitations such as limited host range, high-density biofilm, sub-populate phage resistance in biofilm, and inhibition of phage infection via quorum sensing in biofilm. Therefore, in this review, we specifically discuss the use of phage therapy for inhibition of P. aeruginosa biofilm in clinical and in vitro studies to identify different aspects of this treatment for broader use.
Topics: Anti-Bacterial Agents; Bacteriophages; Biofilms; Combined Modality Therapy; Drug Resistance, Multiple, Bacterial; Humans; Phage Therapy; Pseudomonas aeruginosa
PubMed: 32998720
DOI: 10.1186/s12941-020-00389-5 -
Microbiology (Reading, England) Jan 2020is a Gram-negative opportunistic pathogen and a model bacterium for studying virulence and bacterial social traits. While it can be isolated in low numbers from a wide...
is a Gram-negative opportunistic pathogen and a model bacterium for studying virulence and bacterial social traits. While it can be isolated in low numbers from a wide variety of environments including soil and water, it can readily be found in almost any human/animal-impacted environment. It is a major cause of illness and death in humans with immunosuppressive and chronic conditions, and infections in these patients are difficult to treat due to a number of antibiotic resistance mechanisms and the organism's propensity to form multicellular biofilms.
Topics: Animals; Biofilms; Biological Evolution; Drug Resistance, Bacterial; Genome, Bacterial; Humans; Phylogeny; Pseudomonas Infections; Pseudomonas aeruginosa; Virulence
PubMed: 31597590
DOI: 10.1099/mic.0.000860 -
International Journal of Molecular... Nov 2021In recent years, the effectiveness of antimicrobials in the treatment of infections has gradually decreased. This pathogen can be observed in several clinical cases,... (Review)
Review
In recent years, the effectiveness of antimicrobials in the treatment of infections has gradually decreased. This pathogen can be observed in several clinical cases, such as pneumonia, urinary tract infections, sepsis, in immunocompromised hosts, such as neutropenic cancer, burns, and AIDS patients. Furthermore, causes diseases in both livestock and pets. The highly flexible and versatile genome of allows it to have a high rate of pathogenicity. The numerous secreted virulence factors, resulting from its numerous secretion systems, the multi-resistance to different classes of antibiotics, and the ability to produce biofilms are pathogenicity factors that cause numerous problems in the fight against infections and that must be better understood for an effective treatment. Infections by represent, therefore, a major health problem and, as resistance genes can be disseminated between the microbiotas associated with humans, animals, and the environment, this issue needs be addressed on the basis of an One Health approach. This review intends to bring together and describe in detail the molecular and metabolic pathways in 's pathogenesis, to contribute for the development of a more targeted therapy against this pathogen.
Topics: Animals; Anti-Bacterial Agents; Genomics; Humans; Metabolic Networks and Pathways; Pseudomonas Infections; Pseudomonas aeruginosa; Virulence Factors
PubMed: 34884697
DOI: 10.3390/ijms222312892 -
Microbial Ecology Jul 2014Pseudomonas aeruginosa is a ubiquitous organism that is the focus of intense research because of its prominent role in disease. Due to its relatively large genome and... (Review)
Review
Pseudomonas aeruginosa is a ubiquitous organism that is the focus of intense research because of its prominent role in disease. Due to its relatively large genome and flexible metabolic capabilities, this organism exploits numerous environmental niches. It is an opportunistic pathogen that sets upon the human host when the normal immune defenses are disabled. Its deadliness is most apparent in cystic fibrosis patients, but it also is a major problem in burn wounds, chronic wounds, chronic obstructive pulmonary disorder, surface growth on implanted biomaterials, and within hospital surface and water supplies, where it poses a host of threats to vulnerable patients (Peleg and Hooper, N Engl J Med 362:1804-1813, 2010; Breathnach et al., J Hosp Infect 82:19-24, 2012). Once established in the patient, P. aeruginosa can be especially difficult to treat. The genome encodes a host of resistance genes, including multidrug efflux pumps (Poole, J Mol Microbiol Biotechnol 3:255-264, 2001) and enzymes conferring resistance to beta-lactam and aminoglycoside antibotics (Vahdani et al., Annal Burns Fire Disast 25:78-81, 2012), making therapy against this gram-negative pathogen particularly challenging due to the lack of novel antimicrobial therapeutics (Lewis, Nature 485: 439-440, 2012). This challenge is compounded by the ability of P. aeruginosa to grow in a biofilm, which may enhance its ability to cause infections by protecting bacteria from host defenses and chemotherapy. Here, we review recent studies of P. aeruginosa biofilms with a focus on how this unique mode of growth contributes to its ability to cause recalcitrant infections.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cystic Fibrosis; Disease Models, Animal; Drug Resistance, Bacterial; Humans; Immune System; Pseudomonas aeruginosa; Wounds and Injuries
PubMed: 24096885
DOI: 10.1007/s00248-013-0297-x -
Microbiological Research Mar 2015Bacterial cells can communicate with their surrounding environment through secretion systems. Type VI secretion system (T6SS) is one of the most recently discovered... (Review)
Review
Bacterial cells can communicate with their surrounding environment through secretion systems. Type VI secretion system (T6SS) is one of the most recently discovered secretion systems, which is distributed widely in Gram-negative bacteria such as Pseudomonas aeruginosa (P. aeruginosa), an important opportunistic pathogen. This protein secretion system shares similarity with the puncturing device of bacteriophages in structure. P. aeruginosa is an important opportunistic pathogen and distributes widely in diverse environment. T6SS is beneficial to survival advantage of P. aeruginosa by delivering toxins to its neighboring pathogens and translocating protein effectors into the host cells. T6SS is also the virulence factor and takes part in biofilm formation of P. aeruginosa. The functions of T6SS in P. aeruginosa are regulated at transcriptional, posttranscriptional and posttranslational levels by diverse mechanisms. This article reviews the latest progress in the structure, effector proteins, biological function, and regulation mechanisms of P. aeruginosa T6SS.
Topics: Bacterial Proteins; Bacterial Secretion Systems; Bacterial Toxins; Gene Expression Regulation, Bacterial; Macromolecular Substances; Models, Biological; Models, Molecular; Pseudomonas aeruginosa; Virulence Factors
PubMed: 25721475
DOI: 10.1016/j.micres.2015.01.004 -
Clinical & Experimental Optometry Mar 2018Treatment of Pseudomonas aeruginosa eye infections often becomes a challenge due to the ability of this bacterium to be resistant to antibiotics via intrinsic and... (Review)
Review
Treatment of Pseudomonas aeruginosa eye infections often becomes a challenge due to the ability of this bacterium to be resistant to antibiotics via intrinsic and acquired mechanisms. Transfer of resistance due to interchangeable genetic elements is an important mechanism for the rapid transfer of antibiotic resistance in this pathogen. As a result, drug-resistant strains are becoming increasingly prevalent worldwide. This review systematically analyses data from recent publications to describe the global prevalence and antibiotic sensitivity of ocular P. aeruginosa. Thirty-seven studies were selected for review from PubMed-based searches using the criteria 'microbial keratitis OR eye infection AND Pseudomonas aeruginosa AND antibiotic resistance' and limiting to papers from 2011 onward, to demonstrate the antibiotic resistance from isolates from around the world. Subsequently, we reviewed the ways in which P. aeruginosa can become resistant to antibiotics. Both the rate of isolation of bacteria in general (79 per cent of cases), and prevalence of P. aeruginosa (68 per cent of all isolates) were highest in contact lens-related microbial keratitis. The average resistance rate to common ocular antibiotics such as ciprofloxacin (9 per cent), gentamicin (22 per cent) and ceftazidime (13 per cent) remained relatively low. However, there were large variations in resistance rates reported in studies from different countries, for example resistance to ciprofloxacin reached up to 33 per cent. We next reviewed the types of mobile genetic elements (MGEs) such as plasmids, integrons and transposons that are frequently associated with drug resistance in P. aeruginosa. MGEs are important for the transmission of resistance to beta-lactams and aminoglycosides and recently have been shown to be potential factors for the transmission of fluoroquinolone resistance. Studies on the molecular mechanisms of resistance transfer in ocular P. aeruginosa have begun to be reported and will provide valuable information on the emergence of new antibiotic resistance and potential to treat resistant strains.
Topics: Corneal Ulcer; Drug Resistance, Microbial; Eye Infections, Bacterial; Humans; Pseudomonas Infections; Pseudomonas aeruginosa
PubMed: 29044738
DOI: 10.1111/cxo.12621 -
Microbiology Spectrum Apr 2015Proteinaceous components of the biofilm matrix include secreted extracellular proteins, cell surface adhesins, and protein subunits of cell appendages such as flagella... (Review)
Review
Proteinaceous components of the biofilm matrix include secreted extracellular proteins, cell surface adhesins, and protein subunits of cell appendages such as flagella and pili. Biofilm matrix proteins play diverse roles in biofilm formation and dissolution. They are involved in attaching cells to surfaces, stabilizing the biofilm matrix via interactions with exopolysaccharide and nucleic acid components, developing three-dimensional biofilm architectures, and dissolving biofilm matrix via enzymatic degradation of polysaccharides, proteins, and nucleic acids. In this article, we will review functions of matrix proteins in a selected set of microorganisms, studies of the matrix proteomes of Vibrio cholerae and Pseudomonas aeruginosa, and roles of outer membrane vesicles and of nucleoid-binding proteins in biofilm formation.
Topics: Bacterial Proteins; Biofilms; Extracellular Matrix; Pseudomonas aeruginosa; Secretory Vesicles; Vibrio cholerae
PubMed: 26104709
DOI: 10.1128/microbiolspec.MB-0004-2014